1. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;16:843–862.2. Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct Target Ther 2021;6:402.

3. Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:2503–2512.

4. McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 2021;384:1227–1239.

5. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-tosevere atopic dermatitis: A randomized clinical trial. JAMA Dermatol 2021;157:1047–1055.

6. Boneschansker L, Ananthakrishnan AN, Burke KE, Kochar BD, Lopes EW, Khalili H, et al.; Massachusetts General Hospital Crohn’s And Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: Real-world data. Clin Gastroenterol Hepatol 2023;21:2427–2429.e1.

7. Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D’Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med 2023;388:1966–1980.

8. van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019;394:2108–2117.

9. Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 2019;58:i43–i54.

10. Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritisassociated uveitis. Clin Rheumatol 2020;39:847–851.

11. Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2019;27:1232–1234.

12. Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2018;13:53–55.

13. Pyare R, Dutta Majumder P, Shah M, Kaushik V, Agarwal M, Biswas J. Tofacitinib in scleritis: A case series. Ocul Immunol Inflamm 2024;32:884–890.

14. Ramanan AV, Guly CM, Keller SY, Schlichting DE, de Bono S, Liao R, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: Study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial ( JUVEBRIGHT). Trials 2021;22:689.

15. Duggan S, Keam SJ. Upadacitinib: First Approval. Drugs 2019;79:1819–1828.

16. Napolitano M, D’Amico F, Ragaini E, Peyrin-Biroulet L, Danese S. Evaluating upadacitinib in the treatment of moderate-to-severe active ulcerative colitis: Design, development, and potential position in therapy. Drug Des Devel Ther 2022;16:1897–1913.

17. Schneider J, Schalenbourg A, Dudler J, Guex-Crosier Y. Intermediate uveitis in an HLA-B27-positive patient treated with upadacitinib. Klin Monbl Augenheilkd 2022;239:572–574.

18. Baquet-Walscheid K, Heinz C, Heiligenhaus A. Beneficial effect of upadacitinib in a refractory course of scleritis: A case report. Ocul Immunol Inflamm 2024;32:1076–1078.

19. Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A. Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: A case report. Ocul Immunol Inflamm 2023;31:1079–1080.

20. Tao T, He D, Peng X, Huang Z, Su W. Successful remission with upadacitinib in two patients with anti-TNF-refractory macular edema associated with Behçet’s uveitis. Ocul Immunol Inflamm 2024;32:1897–1900.

21. Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, et al. Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of (( S)-2,2- Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol- 4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)methanone (PF-06700841). J Med Chem 2018;61:8597–8612.

22. Pietschke K, Holstein J, Meier K, Schäfer I, Müller- Hermelink E, Gonzalez-Menendez I, et al. The inflammation in cutaneous lichen planus is dominated by IFN- and IL-21-A basis for therapeutic JAK1 inhibition. Exp Dermatol 2021;30:262–270.

23. Huang Z, Jiang Q, Chen J, Liu X, Gu C, Tao T, et al. Therapeutic effects of upadacitinib on experimental autoimmune uveitis: Insights from single-cell analysis. Invest Ophthalmol Vis Sci 2023;64:28.

24. Mysler E, Burmester GR, Saffore CD, Liu J, Wegrzyn L, Yang C, et al. Safety of upadacitinib in immune-mediated inflammatory diseases: Systematic literature review of indirect and direct treatment comparisons of randomized controlled trials. Adv Ther 2024;41:567–597.

25. Wang F, Sun L, Wang S, Davis JM 3rd, Matteson EL, Murad MH, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: A systematic review and meta-analysis. Mayo Clin Proc 2020;95:1404–1419.

26. Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 2019;58:1755–1766.

27. Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: Focus on herpes zoster. Ther Adv Musculoskelet Dis 2020;12:1759720X20936059.

28. Misra DP, Pande G, Agarwal V. Cardiovascular risks associated with Janus kinase inhibitors: Peering outside the black box. Clin Rheumatol 2023;42:621–632.

29. Minos E, Barry RJ, Southworth S, Folkard A, Murray PI, Duker JS, et al. Birdshot chorioretinopathy: Current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet J Rare Dis 2016;11:61.